Develops antibody therapies for inflammatory disease and earns royalties on antibodies it discovered and licensed to partners.
Develops antibody therapies for inflammatory disease and earns royalties on antibodies it discovered and licensed to partners.
Does not sell a medicine itself: its income is a royalty on GSK's sales of Jemperli, a cancer antibody it discovered, plus milestone payments, which it uses to fund its own inflammatory-disease pipeline.
Moat: narrow (IP / patents, process know-how). Proprietary antibody generation platform has produced multiple partnered, royalty-bearing approved drugs.
Headquarters: San Diego, California, US · Founded: 2005 · Employees: 104
Size AnaptysBio (ANAB) is a United States Health Care company (Biotechnology) with a market value of $1.40B, the 2014th largest of 3,085 United States companies the cockpit tracks. Shares closed at $47.06 on 18 Nov 2026.
Performance Over six months the shares fell 21.7%, against -17.2% for the median peer and -2.2% for the United States market (cap-weighted) — 7th lowest of 19 in its peer set.
Growth Revenue grew 13.0% over the last twelve months (peer median +28.0%); the operating margin is 62.2% (peer median -296.1%).
Valuation It trades at 4.9× forward earnings against a peer median of 134.6× (cheapest of 6).
Price implies For today's price to make sense, revenue must grow about 0% a year for seven years (Req g). Recent delivered growth is +26%, so the hurdle is -25 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 63.5 points above its cost of capital (8.8% WACC).
Short interest Short interest is 16.9% of the free float (30 Oct 2026).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $192M | $235M | $91.3M | $17.2M | $10.3M |
| Revenue growth | — | +157% | +432% | +67% | — |
| Gross profit | n/a | $232M | $88.9M | $14.8M | $7.95M |
| EBITDA | $121M | $50.3M | -$113M | -$155M | -$113M |
| Net income | $184M | -$13.2M | -$145M | -$164M | -$129M |
| Free cash flow | $35.9M | $19.6M | -$136M | -$122M | -$74.0M |
| Capital expenditure | $1,000 | $87,000 | $358,000 | $807,000 | $358,000 |
| Total debt | $262M | $291M | $369M | $329M | $324M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| AnaptysBio ANAB | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% |
| AbbVie ABBV | $506B | +35% | +11% | 36% | 18.1× | -0.1% |
| Genmab A/S GMAB.CO | $30.8B | +103% | +15% | 31% | 40.9× | 11.6% |
| Xencor XNCR | $2.58B | +204% | +34% | -73% | n/a | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ANAB | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +3.6% | -15.3% | 2nd highest of 21 |
| 6-month return | -21.7% | -17.2% | 7th lowest of 19 |
| Distance from 52-week high | -35.0% | -47.0% | 5th highest of 21 |
| Revenue growth (TTM) | +13.0% | +28.0% | 7th lowest of 18 |
| Operating margin | 62.2% | -296.1% | highest of 19 |
| Forward P/E | 4.9× | 134.6× | cheapest of 6 |
| Growth the price implies (Req g, 7 yrs) | 0.5% | n/a | — |
| Growth delivered (Del g) | +25.6% | n/a | — |
| Hurdle (Req g minus delivered) | -25.1 pp | n/a | — |
| ROIC minus cost of capital | +63.5 pp | -23.7 pp | highest of 9 |
| EV / EBITDA | 12.4× | n/a | — |
| Net debt / EBITDA | 0.9× | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| AnaptysBio ANAB | United States | $1.40B | -22% | +13% | 62% | 4.9× | 0.5% | +25.6% |
| Rapport Therapeutics RAPP | United States | $1.39B | -34% | n/a | -838% | n/a | n/a | n/a |
| Absci ABSI | United States | $1.41B | +65% | -47% | -9,155% | n/a | n/a | n/a |
| CanSino Biologics 688185.SS | China | $1.38B | 0% | +30% | -4% | 199.3× | n/a | n/a |
| uniQure QURE | United States | $1.42B | -17% | +28% | -1,027% | n/a | n/a | n/a |
| Nanjing Vazyme Biotech 688105.SS | China | $1.42B | +25% | +16% | -5% | 137.8× | 39.4% | -2.5% |
| Oncolys BioPharma 4588.T | Japan | $1.37B | +181% | +1,749% | -295% | n/a | n/a | n/a |
| Intellia Therapeutics NTLA | United States | $1.37B | -20% | -8% | -821% | n/a | n/a | n/a |
| Immunocore Holdings Plc Shs Sponsored American Depositary Shares Repr 1 Sh IMCR | United States | $1.44B | -7% | +13% | -7% | n/a | n/a | n/a |
| Tyra Bioscience TYRA | United States | $1.35B | -41% | n/a | n/a | n/a | n/a | n/a |
| Wuhan Healthgen Biotechnology 688765.SS | China | $1.46B | -51% | +90% | -297% | n/a | n/a | n/a |
| Generate Biomedicines GENB | United States | $1.34B | -20% | +56% | -737% | n/a | n/a | n/a |
| UroGen Pharma URGN | United States | $1.46B | -1% | +159% | -12% | 16.7× | n/a | n/a |
| Nuvation Bio NUVB | United States | $1.34B | -16% | +654% | -61% | n/a | n/a | n/a |
| Fujian Haixi Pharmaceuticals 2637.HK | Hong Kong | $1.47B | -32% | +25% | 33% | 46.4× | n/a | n/a |
| Zhuhai Trinomab Pharmaceutical 688806.SS | China | $1.32B | n/a | +238% | -1,196% | n/a | n/a | n/a |
| Mesoblast MSB.AX | Australia | $1.49B | -17% | +556% | -43% | n/a | n/a | n/a |
| Peptron 087010.KS | South Korea | $1.49B | -68% | -13% | -488% | n/a | n/a | n/a |
| Novavax NVAX | United States | $1.31B | -14% | -61% | -17% | 134.6× | n/a | n/a |
| TLC BioSciences 7924.TWO | Taiwan | $1.50B | n/a | n/a | n/a | n/a | n/a | n/a |
| Taysha Gene Therapies TSHA | United States | $1.30B | -27% | -13% | -2,998% | n/a | n/a | n/a |